Synthesis 2010(8): 1365-1370  
DOI: 10.1055/s-0029-1218673
PAPER
© Georg Thieme Verlag Stuttgart ˙ New York

New Synthetic Methodology for Construction of the 1,3,4,5-Tetrahydro-2H-1,3-benzodiazepin-2-one Skeleton

Cagatay Dengiza, Sevil Özcana,b, Ertan Şahinc, Metin Balci*a
a Department of Chemistry, Middle East Technical University, 06531 Ankara, Turkey
Fax: +90(312)2103200; e-Mail: mbalci@metu.edu.tr;
b Department of Chemistry, Abant Izzet Baysal University, 14280 Bolu, Turkey
c Department of Chemistry, Atatürk University, 25240 Erzurum, Turkey
e-Mail: ertan@atauni.edu.tr;
Further Information

Publication History

Received 13 December 2009
Publication Date:
11 February 2010 (online)

Abstract

We hereby report a new synthetic methodology for construction of the 1,3,4,5-tetrahydro-2H-1,3-benzodiazepin-2-one skeleton. 2-(2-Carboxyethyl)benzoic acid was converted into the corresponding bis(acyl azide). Curtius rearrangement of the diazide followed by reaction with alcohols provided diurethane derivatives. Ring-closure reaction of the diurethanes with base resulted in formation of the 1,3-benzodiazepin-2-one skeleton.

    References

  • 1a Archer GA. Sternbach LH. Chem. Rev.  1968,  68:  747 
  • 1b Sternbach LH. Prog. Drug Res.  1978,  22:  229 
  • See, for example:
  • 2a Costa B. Salvetti A. Rossi L. Spinetti F. Lena A. Chelli B. Rechichi M. Da Pozzo E. Gremigni V. Martini C. Mol. Pharmacol.  2006,  69:  37 
  • 2b Sternbach LH. J. Med. Chem.  1979,  22:  1 
  • 2c Bolli MH. Marfurt J. Grisostomi C. Boss C. Binkert C. Hess P. Treiber A. Thorin E. Morrison K. Buchmann S. Bur D. Ramuz H. Clozel M. Fischli W. Weller T. J. Med. Chem.  2004,  47:  776 
  • 2d Torres SRR. Nardi GM. Ferrara P. Ribeiro-do-Valle RM. Farges RC. Eur. J. Pharmacol.  1999,  385:  R1 
  • 2e Boojamra CG. Burow KM. Thompson LA. Ellman JA. J. Org. Chem.  1997,  62:  1240 
  • 2f Keating TA. Armstrong RW. J. Org. Chem.  1996,  61:  8935 
  • 2g Webb RR. Barker PR. Baier M. Reynolds ME. Robarge KD. Blackburn BK. Tichler MH. Weese KJ. Tetrahedron Lett.  1994,  35:  2113 
  • 3a inventors; (Boehringer Ingelheim Pharma GmbH & Co. KG, Germany) Eur. Pat. Appl. EP 2065382  A1. 
  • 3b Gottschling D, Dahmann G, Doods H, Heimann A, Mueller SG, Rudolf K, Schaenzle G, and Stenkamp D. inventors; PCT Int. Appl. WO 2009065919  A2. 
  • 3c Nichols PL, Skidmore J, Ward RW, and Wilson DM. inventors; PCT Int. Appl. WO 2009000819  A1. 
  • 3d Schnaubelt J, Stehle E, and Krueger T. inventors; PCT Int. Appl. WO 2007074130  A2. 
  • 4a Yoshida T. Kambe N. Murai S. Sonoda N. Bull. Chem. Soc. Jpn.  1987,  60:  1793 
  • 4b Yoshida T. Kambe N. Murai S. Sonoda N. Tetrahedron Lett.  1986,  27:  3037 
  • 4c Jen T. Bender P. Van Hoeven H. Dienel B. Loev B. J. Med. Chem.  1973,  16:  407 
  • 5 Han X. Civiello RL. Mercer SE. Macor JE. Dubowchik GM. Tetrahedron Lett.  2009,  50:  386 
  • 6 Page GA. Tarbell DS. Org. Synth.   1954,  34:  8 
  • 7a Koza G. Ozcan S. Şahin E. Balci M. Tetrahedron  2009,  65:  5973 
  • 7b Ozcan S. Balci M. Tetrahedron  2008,  64:  5531 
  • 7c Ozcan S. Şahin E. Balci M. Tetrahedron Lett.  2007,  48:  215 
  • 8 Murai N. Komatsu M. Yagii T. Nishihara H. Ohshiro Y. Agawa T. J. Org. Chem.  1977,  42:  847 
  • 9a Tsuritani T. Yamamoto Y. Kawasaki M. Mase T. Org. Lett.  2009,  11:  1043 
  • 9b Blout ER. Silverman DC. J. Am. Chem. Soc.  1944,  66:  1442 
  • 9c Entwistle ID. Tetrahedron Lett.  1979,  555